1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity

X Zhu,J-M Sun,J Sun,E Van Cutsem,C-H Lu,I-H Kim,F Wang,R-H Xu,S-B Kim,Y Pan,C-Y Lin,Z Chen,R Ge,D Tougeron,R Abdrashitov,J Zhang,J Zhou

doi:10.1016/j.annonc.2023.09.2159

1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity

X Zhu, J-M Sun + Show 15 more

https://doi.org/10.1016/j.annonc.2023.09.2159

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: KU Leuven, Chiayi Chang Gung Memorial Hospital, Seoul St. Mary's Hospital, Sun Yat-sen University Cancer Center, Asan Medical Center, Anhui Provincial Hospital, Liaoning Cancer Hospital & Institute

#Programmed Cell Death-ligand 1 #Esophageal Squamous Cell Carcinoma + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity

Full Text